A repurposed FDA-approved drug shows promise in killing antibiotic resistant bacteria
A study of Acinetobacter baumannii employed an entirely new strategy to identify weaknesses specific to resistant bacteria and then target these weaknesses with an alternate drug. They found that fendiline kills the bacterium by targeting the essential lipoprotein trafficking pathway, which is weakened in antibiotic resistant bacteria.
Registered users, subscribers or members - SIGN IN
To continue reading this article
Membership
Included as a benefit
Members of Applied Microbiology International have unlimited access to The Microbiologist as a benefit of membership. Just sign in with your usual membership credentials.
Find out more about how to join.
Register
FREE
Want to read more before deciding on a subscription? It only takes a minute to sign up for a free account and you’ll get to enjoy more free content each month.
Subscribe
3.75 per month / £35 annually
Get unlimited access to The Microbiologist.